Nina Weisser
Company: Zymeworks
Job title: Director - Multispecific Antibody Therapeutics
Seminars:
Using Trispecific T-Cell Engagers Alongside Checkpoint Inhibition to Enhance the Therapeutic Applications of TCEs 3:15 pm
Combining trispecific T-cell engagers with checkpoint inhibition to simultaneously target tumor cells, activate T-cells, and block immune suppressive pathways, enhancing antitumor immunity Optimizing trispecific T-cell engager design to improve tumor specificity, T-cell recruitment, and immune checkpoint blockade for synergistic therapeutic effects Exploring the clinical potential of trispecific engagers with checkpoint inhibitors in solid and hematologic…Read more
day: Day 2